Adicet reports third quarter 2023 financial results and provides business updates

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended september 30, 2023. “clinical and translational medicine data for our lead asset adi-001 in nhl has provided us with valuable insights, which has guided us as we initiated the expand cohort in post car t lbcl and.
ACET Ratings Summary
ACET Quant Ranking